Today: 10 June 2026
Browse Category

NASDAQ:RVPH 24 October 2025 - 9 March 2026

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals enacted a 1-for-20 reverse stock split early Monday to boost its share price and avoid a Nasdaq delisting. The company faces a March 27 deadline to meet the $1 minimum bid rule. Reviva is also seeking funding for a new Phase 3 trial of its schizophrenia drug after the FDA requested more data. Analyst Jason Kolbert downgraded the stock, citing unchanged fundamentals.
9 March 2026
·
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.
10 December 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···

Stock Market Today

  • Stock Market Update June 9: Nasdaq Slumps Amid Tech Sell-Off and Risk-Off Sentiment
    June 9, 2026, 6:04 PM EDT. On June 9, the S&P 500 declined 0.26% to 7,386.65, and the Nasdaq Composite dropped 0.97% to 25,678.82, pressured by a renewed sell-off in technology and semiconductor stocks. Broadcom, Micron, AMD, and Intel led the losses, while Microsoft and Apple also fell despite new partnerships and AI capability concerns, respectively. The Dow Jones Industrial Average marginally rose 0.17% after a late recovery. Market volatility stemmed from profit-taking, risk reduction ahead of key U.S. inflation data, geopolitical tensions, and repositioning ahead of SpaceX's mega-IPO. Diversification is advised as investors shift away from tech to mitigate concentration risks. Meanwhile, The Motley Fool's Stock Advisor highlighted its top 10 growth stocks, excluding the S&P 500, emphasizing long-term investing opportunities.

Latest articles

Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

9 June 2026
Opendoor shares rose 0.8% to $4.34 as investors positioned for its pending inclusion in the Russell 3000, set to take effect after June 26; index entry can boost demand from passive funds, but Opendoor’s Q1 revenue fell to $720 million with a wider $173 million net loss, and the company warned of risks from mortgage-rate volatility and housing market swings.
T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

9 June 2026
T1 Energy shares plunged 7.4% to $8.46 after a new filing revealed details on stock-based payments for the KORE Power acquisition, raising dilution concerns as the deal’s share count will be set by a 10-day VWAP; a lower VWAP could mean more shares issued, pressuring existing holders amid sector-wide weakness and ongoing risks to closing and financing.
Navitas Tumbles as $500 Million Stock Sale Interrupts Nvidia Surge

Navitas Tumbles as $500 Million Stock Sale Interrupts Nvidia Surge

9 June 2026
Navitas Semiconductor shares plunged 6.6% to $22.85 after unveiling a $500 million stock-sale program, a board resignation, and weaker chip sector sentiment, as investors weighed dilution risks and uncertainty around AI-infrastructure demand despite a new product launch and recent ties to Nvidia’s MGX ecosystem.
Epsium Enterprise Shares Surge 72% in Volatile Nasdaq Trading

Epsium Enterprise Shares Surge 72% in Volatile Nasdaq Trading

9 June 2026
Epsium Enterprise soared 72.27% to close at $2.05 on record volume over 65 million shares—more than 200 times its average—before dropping 18.54% after hours to $1.67, as traders piled into the volatile Macau beverage wholesaler despite no major news and fundamentals showing falling revenue and a net loss.
Go toTop